ArticleNPJ genomic medicine2026
New insights into neurodevelopmental disorders by whole genome sequencing of 100 families from Italy.
Article in NPJ genomic medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
31 authors.
Funding
Abstract
Neurodevelopmental disorders (NDDs) have a strong but largely unexplained genetic basis. Moreover, the genetic architecture of these complex disorders in under-represented communities is poorly studied. We analyzed 110 probands from 100 families (for a total of 298 individuals), using whole genome sequencing (WGS) to identify genetic contributors to NDDs. This study is part of the '5000genomi@VdA' project characterizing Valle d'Aosta (Italy) genomic landscape in health and disease. Probands were stratified into three diagnostic categories: ASD (autism spectrum disorder without intellectual disability), ID (intellectual disability without ASD), and ASD-ID (autism spectrum disorder with comorbid intellectual disability). Following the ACMG guidelines, we identified 32 likely phenotype-causing variants in known NDD-associated genes in 26.4% of the probands. We observed a diagnostic yield gradient, lowest in ASD, intermediate in ASD-ID, and highest in ID. We also identified 42 variants of uncertain significance, 14 of which were located in genes not previously linked to NDDs but relevant to neurodevelopment, and may thus represent new NDD candidate genes. Furthermore, we used Evo 2, an evolutionary constraint-based model, to refine variant interpretation and identify VUS with pathogenic-like signatures. These findings highlight the utility of WGS in exploring the genetic heterogeneity within stratified NDD clinical groups.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.